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Importance 
Ebolaviruses and marburgviruses are incompletely understood pathogens that 
cause severe, often fatal, illnesses in humans and non-human primates. These diseases 
have been known as Ebola and Marburg hemorrhagic fevers, respectively, after the 
most dramatic symptoms in severe cases. The names “Ebola virus disease” or 
Marburg virus disease” are now preferred by the World Health Organization (WHO) 
and some other groups.  
Most species of ebolaviruses and the only known species of marburgvirus occur 
in Africa. Current evidence suggests that the reservoir hosts are probably bats, while 
other animals and people are incidental hosts. Humans seem to become infected with 
marburgviruses mainly in caves or mines harboring bats, while ebolavirus infections 
are often associated with handling tissues from infected nonhuman primates and other 
species. Once a virus has entered human populations, it can spread from person to 
person. Some epidemics have affected hundreds of people, particularly when 
nosocomial spread occurs from inadequate medical supplies or barrier nursing 
procedures, or when outbreaks are not recognized for long periods. An outbreak of 
unprecedented size in West Africa began in December 2013, and was first recognized 
in March 2014. It has been spread in some densely populated urban regions, and has 
affected thousands of people to date. Although the mortality rate has varied between 
outbreaks, some ebolaviruses or marburgviruses have killed up to 90% of those who 
become infected. Treatment options are limited, and with the exception of 
experimental treatments, consist of supportive care alone. Epizootics in gorillas and 
chimpanzees are equally serious, and may threaten the survival of these species in the 
wild. Other wild mammals including duikers also seem to be killed during outbreaks.  
One species, Reston ebolavirus, has been reported outside Africa, in the 
Philippines and China. This virus does not seem to affect humans, although some 
people may seroconvert. However, it can cause fatal illness in some species of 
nonhuman primates. Between 1989 and 1996, Reston ebolavirus was isolated 
repeatedly at primate quarantine facilities in the U.S. and Italy; in all but one instance, 
infected monkeys had been imported from a single facility in the Philippines. The 
source of the virus was never found, but infected monkeys do not seem to have been 
exported after this facility was closed in 1997. In 2008, however, Reston ebolavirus 
was discovered in pigs during an unusually severe outbreak of porcine reproductive 
and respiratory syndrome (PRRS) in the Philippines. This virus was also found in pigs 
with PRRS in China. Based on experimental studies, Reston ebolavirus alone does not 
seem to cause any illness in pigs, although its effects during co-infections with other 
pathogens have not yet been evaluated. Accumulating evidence suggests that 
ebolaviruses or their relatives may also occur in other locations, although the clinical 
significance of these viruses for humans and domesticated animals is uncertain.   
Etiology 
Ebola and Marburg hemorrhagic fevers are caused by members of the genera 
Ebolavirus and Marburgvirus, respectively, in the family Filoviridae. The names of 
these viruses have undergone several taxonomic changes since they were first 
discovered, including new changes officially accepted in 2013. Currently, the genus 
Ebolavirus contains five recognized viral species: Zaire ebolavirus, Sudan ebolavirus, 
Taï Forest ebolavirus (formerly Cote d’Ivoire ebolavirus), Reston ebolavirus and 
Bundibugyo ebolavirus. The common name for the single virus in each of these 
species is Ebola virus (formerly Zaire ebolavirus), Sudan virus (formerly Sudan 
ebolavirus), Tai Forest virus (formerly Cote d’Ivoire ebolavirus), Reston virus 
(formerly Reston ebolavirus) and Bundibugyo virus. Marburgvirus contains a single 
species, Marburg marburgvirus (formerly Lake Victoria marburgvirus), and two 
individual viruses, Marburg virus and Ravn virus, within this species.  
A third genus, Cuevavirus, (species Lloviu cuevavirus; Lloviu virus) has been 
proposed for a filovirus found during an outbreak of viral pneumonia among  
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Schreiber's bats (Miniopterus schreibersii) in Europe. Very 
little is known about Lloviu virus. To date, it has not been 
isolated in culture, or found in other species. 
[Note: because the distinctions between terms such as 
‘Ebola virus,’ ‘ebolaviruses,’ ‘Zaire ebolavirus’ and the 
recently used common name ‘Zaire ebolavirus’ can be 
confusing, specific viruses are identified by species name 
rather than common name in this factsheet.] 
Species Affected 
Reservoir hosts 
Bats are thought to be the reservoir hosts for 
filoviruses, and appear to carry these viruses 
asymptomatically. Antibodies to ebolaviruses and/or viral 
RNA have been found in a number of bat species in Africa, 
with a high seroprevalence in several species of fruit bat. 
All studies to date have examined bats for Zaire ebolavirus 
or Reston ebolavirus, although the other ebolaviruses are 
probably also maintained in these animals. Outside Africa, 
antibodies to Reston ebolavirus were found in a species of 
fruit bat (Rousettus amplexicaudatus) in the Philippines. 
The cave-dwelling Egyptian fruit bat (Rousettus 
aegyptiacus) seems to be the primary host for Marburg 
marburgvirus, although evidence of infection has been 
found in other fruit bats and insectivorous bats. Marburg 
marburgvirus is the only filovirus, to date, that has actually 
been isolated from the tissues of bats in the wild. 
Surveillance among wildlife is incomplete, and it is 
possible that other reservoir or amplifying hosts also exist. 
In 1998, Zaire ebolavirus RNA was found in six mice (Mus 
setulosus and Praomys sp) and a shrew (Sylvisorex ollula), 
and these species were proposed as possible reservoir hosts. 
However, these results have not been confirmed by other 
groups, and virus isolation was unsuccessful. Domesticated 
pigs have also been suggested as possible amplifying and/or 
maintenance hosts for some viruses. 
African filoviruses 
The African filoviruses (all filoviruses except Reston 
ebolavirus) can cause severe illness in nonhuman primates 
and some other animals. African ebolaviruses and Marburg 
marburgvirus are typically lethal in experimentally infected 
nonhuman primates. In Africa, ebolavirus outbreaks have 
been linked to reports of dead and dying gorillas (Gorilla 
gorilla), chimpanzees (Pan troglodytes), mandrills 
(Mandrillus sp.), guenon (Cercopithecus sp.) and other 
nonhuman primates, as well as duikers (a species of forest 
antelope, Cephalophus dorsalis), bush pigs (red river hog, 
Potamochoerus porcus), brush-tailed porcupines (Atherurus 
africanus) and other animals. While there is no formal 
evidence for a causative role in some species, attempts to 
isolate ebolaviruses or detect viral RNA were successful in 
the carcasses of chimpanzees, gorillas and duikers. 
Antibodies to filoviruses have been reported in nonhuman 
primates including mandrills, drills (Mandrillus sp.), 
baboons (Papio sp.), colobus monkeys (Colobus badius), 
guenon, chimpanzees and gorillas. . 
There have been no reports of illnesses or unusual 
deaths among domesticated animals during ebolavirus 
outbreaks in Africa. One study detected antibodies in dogs, 
but did not find virological evidence of infection at the time 
the study was conducted. What these antibodies indicate is 
currently uncertain, as 1) some filoviruses are cross-reactive 
in serological tests, and 2) the dogs could have either been 
infected with ebolaviruses or exposed without productive 
infection. One pet dog exposed to its Zaire ebolavirus-
infected owner in the U.S. did not become infected. Older 
serological studies sometimes reported antibodies in guinea 
pigs, some livestock, and even chickens in Africa, but they 
used a serological test (IFA) that is no longer considered to 
be reliable. Viruses were not found during very limited 
sampling of live cattle, sheep, goats and pigs during 
outbreaks. Some animal species (e.g., sheep and goats) 
were described as “completely insensitive” to the effects of 
the virus when inoculated with large amounts of live 
ebolaviruses for the production of hyperimmune serum in 
Russian studies, but whether this indicates asymptomatic 
infection or complete absence of virus replication seems to 
be uncertain. Pigs have been infected experimentally with 
Zaire ebolavirus and developed respiratory signs. Various 
laboratory rodents are used as models for human disease; 
however, the viruses used have been artificially adapted to 
replicate at high levels in these animals.  
Reston ebolavirus 
Other than bats, Reston ebolavirus has been found in 
nature only in nonhuman primates (e.g., cynomolgus 
macaques, Macaca fascicularis), which become ill, and 
domesticated pigs. Whether Reston ebolavirus can be 
maintained long term in swine populations is not known. In 
one study, this virus caused severe clinical signs in 
cynomolgus monkeys, but minimal or no signs in African 
green monkeys inoculated intraperitoneally with the same 
virus, despite evidence of viremia in the latter species. 
Zoonotic potential 
Zaire ebolavirus, Sudan ebolavirus, Bundibugyo 
ebolavirus and Tai Forest ebolavirus can cause severe 
illness in humans, although Tai Forest ebolavirus infections 
have rarely been documented. Reston ebolavirus does not 
seem to be pathogenic for humans, but people may 
seroconvert after exposure to infected nonhuman primates 
or pigs.  
Geographic Distribution 
Zaire ebolavirus, Sudan ebolavirus, Tai Forest 
ebolavirus and Bundibugyo ebolavirus are endemic in parts 
of Africa south of the Sahara desert. Human illnesses 
caused by these viruses have been reported mainly in 
central and western Africa, and have typically been 
associated with rain forests. While outbreaks have been 
documented in a limited number of countries, serological 
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surveys, as well as the distribution of bat species known to 
be infected, suggest that some viruses may be more 
widespread.  
Marburg marburgvirus has been found in bats, 
nonhuman primates and/or humans from eastern Africa to 
the far western edge of the Congo. The human illness seems 
to be most prevalent in eastern Africa, although one 
outbreak was documented in Angola (western Africa). A 
case reported from South Africa was most likely acquired 
in Zimbabwe. Imported human cases have been seen 
sporadically in other areas, including Europe and North 
America. In recent decades, such cases have mainly been 
reported among travelers returning from Africa, but a large 
Marburg hemorrhagic fever outbreak occurred in Germany 
and Yugoslavia in 1967, among laboratory workers who 
had been exposed to tissues from imported African green 
(vervet) monkeys (Cercopithecus aethiops). 
Reston ebolavirus occurs in the Philippines, and has 
also been reported in PRRS virus-infected pigs from a 2008 
outbreak in China. This or other filoviruses might also exist 
in other locations. Antibodies to filoviruses have been 
detected in several species of fruit bats in China and 
Bangladesh, and 18% of healthy Bornean orangutans 
(Pongo pygmaeus) in rehabilitation facilities were 
seropositive on Kalimantan Island, Indonesia. Outbreaks 
among imported, nonhuman primates in the United States 
and Italy were eradicated.  
Transmission 
How filoviruses are transmitted between bats, or 
transmitted from bats to other animals, is still uncertain. 
Although these viruses can be found in bat tissues and 
blood, they typically seem to be absent from secretions or 
excretions such as oral fluids, urine and feces (although 
virus was found in the feces of one experimentally infected 
bat), and attempts to inoculate bats by exposing respiratory 
and oral mucus membranes to virus were unsuccessful. It is 
possible that virus shedding in secretions and excretions 
occurs intermittently, at very low levels and/or under 
certain physiological conditions. There is some evidence 
that transmission might occur when bats give birth. 
Seasonal changes in the prevalence of Marburg 
marburgvirus RNA were reported in older juvenile 
Egyptian fruit bats, with peaks during the twice-yearly 
birthing seasons. These peaks seem to coincide with a 
higher risk of human infection. Pregnant fruit bats are also 
more likely to be seropositive than nonpregnant females. . 
Filoviruses emerge periodically in nonhuman primates 
or people after infection from an outside source. Most 
Marburg marburgvirus infections in humans have been 
associated with transmission within caves, probably from 
infected bats, although some people were infected by 
exposure to nonhuman primate tissues in the laboratory. 
Some ebolaviruses might also be acquired directly from 
bats; however, humans often become ill after handling the 
carcasses of animals found in the forest, especially 
nonhuman primates and duikers. Blood, secretions and 
excretions, and tissues from these animals may contain 
infectious virus. Filoviruses have been reported to survive 
for some time in blood and tissues at room temperature, and 
can be transmitted on fomites, particularly those 
contaminated by blood. Survival is prolonged when viruses 
are kept at 4°C. In incidental hosts, filoviruses are thought 
to enter the body mainly through mucous membranes and 
broken skin. Arthropod-borne transmission is theoretically 
possible, but most authors suggest it is unlikely.  
Once ebolaviruses or marburgviruses have infected 
humans, they can spread from person to person. Viruses 
mostly seem to occur in secretions and excretions only after 
the onset of fever, and the amount of virus increases as the 
disease becomes more severe. Blood can contain large 
amounts of virus, contaminating the environment if patients 
hemorrhage. These viruses are also found in many 
secretions and excretions that are not visibly contaminated 
with blood, including saliva, tears, breast milk, semen and 
feces. Urine may be a source of virus, but Zaire ebolavirus 
was absent from patients’ urine during one outbreak. 
Aerosol and/or respiratory droplet transmission between 
nonhuman primates is still controversial: it has been 
implicated in some experimentally infected nonhuman 
primates, but alternative explanations may be possible, and 
virus did not seem to spread readily between cages in other 
studies. While people might theoretically become infected 
by this route, aerosols do not seem to be important during 
human outbreaks. Filoviruses disappear from blood and 
most tissues either during or soon after recovery. They may, 
however, persist for a time in some “immune privileged” 
body sites, such as the testes and the anterior chamber of 
the eye. While persistence within the eye does not seem to 
lead to virus shedding (virus was found for only 10 days in 
conjunctival secretions, after clearance from the blood), 
sexual transmission is a significant risk. Marburg 
marburgvirus has been transmitted sexually, 13 weeks after 
the onset of disease, and Zaire ebolavirus has been isolated 
from the semen of convalescent patients up to 82 days after 
the onset of clinical signs, and detected by RT-PCR for as 
long as 16 months. This virus was also recovered from the 
breast milk of a convalescing patient, 15 days after the 
onset of disease (after the virus had been cleared from the 
blood), and transmission to a nursing child may be possible. 
There is also good evidence for vertical transmission to the 
fetus, in humans How efficiently filoviruses can spread by 
casual contact during the early stages of the illness is still 
uncertain, but the risk is currently thought to be low except 
during close contact.  
The extent of transmission between nonhuman 
primates during outbreaks in the wild is controversial; 
however, current evidence suggests that these viruses are 
not spread efficiently, and nonhuman primates are unlikely 
to act as maintenance hosts. Virus spread is likely to depend 
on the extent of interactions between members of the 
population, as well as the infectivity of body fluids and 
Ebolavirus and Marburgvirus Infections 
Last Updated: August 2014 © 2009-2016 page 4 of 13 
carcasses. Most other species (e.g., duikers) have not been 
examined, but the role of domesticated pigs is under 
investigation. Young pigs (3-6 months of age) inoculated 
with either Zaire ebolavirus or Reston ebolavirus shed these 
viruses in nasal and oral fluids, and evidence of infection 
was also found sometimes in blood, rectal swabs and 
various tissues. Pigs infected with Zaire ebolavirus 
transmitted this virus to pigs in close contact, as well as to 
cynomolgus macaques housed in the same room but not in 
direct contact with the pigs. In pigs infected with Reston 
ebolavirus, the virus had disappeared from blood and 
tissues by one month after infection. Whether sustained 
transmission of ebolaviruses can occur in swine populations 
has not yet been determined.  
Disinfection 
Ebolaviruses and marburgviruses are both reported to 
be susceptible to sodium hypochlorite, glutaraldehyde, β-
propiolactone, 3% acetic acid (pH 2.5), formaldehyde and 
paraformaldehyde. Recommended dilutions of sodium 
hypochlorite may vary with the use. Calcium hypochlorite, 
peracetic acid, methyl alcohol, ether, sodium deoxycholate 
and some other agents have also been tested against 
ebolaviruses, and found to be effective. In addition, 
filoviruses can be inactivated by ultraviolet light, gamma 
irradiation, heating to 60°C (140°F) for 60 minutes or 
boiling for 5-20 minutes.  
Infections in Animals 
Incubation Period 
Experimental inoculation of nonhuman primates with 
filoviruses often results in clinical signs after 3-5 days, 
although the incubation period was reported to be as long as 
16 days in some animals. Pigs developed a fever 4 days 
after inoculation with Zaire ebolavirus. 
Clinical Signs 
Nonhuman primates are severely affected by 
filoviruses. Wild chimpanzees and gorillas are often found 
dead. Clinical signs observed in dying wild animals (of 
various species) during ebolavirus outbreaks have included 
vomiting, diarrhea, hair loss and emaciation, as well as 
bleeding from the nostrils. Whether all of these signs are 
associated with filovirus infections or some were caused by 
other diseases is uncertain. During the 1989 Reston 
ebolavirus outbreak in Virginia, the clinical signs in 
cynomolgus monkeys included anorexia, swollen eyelids, 
increased lacrimation, nasal discharge, coughing and 
splenomegaly. Fever, subcutaneous hemorrhages, epistaxis 
and/or bloody diarrhea were less common. These animals 
were also infected with simian hemorrhagic fever virus; 
thus, the contributions of each virus to the signs were 
uncertain. The most common clinical signs at the infected 
exporting facility were respiratory signs and diarrhea, while 
hemorrhages occurred but were rare (1% of animals). 
However, these signs were reported in both infected and 
uninfected animals, and some cynomolgus monkeys that 
died with Reston ebolavirus infection had no apparent signs 
before death.  
Nonhuman primates that are experimentally infected 
with filoviruses may develop fever, anorexia, vomiting, 
diarrhea, dyspnea, splenomegaly and weight loss. A skin 
rash is common, although it can be absent in some species, 
or in animals inoculated by certain routes. Hemorrhagic 
signs may include petechiae, bleeding into the 
gastrointestinal tract, or bleeding from puncture wounds 
and mucous membranes. Shock and hypothermia are soon 
followed by death. African species of ebolaviruses are 
usually more pathogenic than Reston ebolavirus: the 
clinical signs are more severe, hemorrhages are more 
common and the mortality rate is higher 
Piglets (approximately 5-6 weeks of age) inoculated 
with Zaire ebolavirus developed a fever and respiratory 
signs, which progressed to dyspnea, anorexia and lethargy, 
while less severe respiratory signs occurred in slightly 
younger piglets inoculated with the same virus. Guinea pigs 
infected with unpassaged filoviruses from primates may 
have a fever and weight loss, but recover. In this species, 
severe illness is only seen in animals infected with serially 
passaged virus adapted to guinea pigs. No clinical signs 
have been reported in infected wild bats, and 
experimentally infected bats remain asymptomatic.  
Reston ebolavirus does not seem to causes any illness 
in experimentally inoculated pigs. However, this virus has 
been detected in pigs with porcine reproductive and 
respiratory syndrome in both the Philippines and China, and 
whether it can exacerbate other illnesses or predispose 
animals to other infections is unknown. The PRRS outbreak 
in the Philippines and China were unusually severe, but 
consistent with other outbreaks caused by atypical PRRS 
viruses. Some of the pigs in the Philippines were also 
infected with porcine circovirus type 2.  
Post Mortem Lesions 
Hemorrhagic signs (especially petechiae and 
ecchymoses) may be found in various internal organs, the 
skin and mucous membranes. The liver, spleen, lymph 
nodes, adrenal glands and some other organs may be 
enlarged and/or congested and friable. The liver may be 
severely reticulated and discolored. Some species have a 
maculopapular rash. Microscopic lesions include focal to 
widespread hepatocyte necrosis, necrosis of the zona 
glomerulosa of the adrenal cortex; signs of lymphoid 
depletion (with apoptosis and necrosis) in lymphoid tissues 
including lymph nodes and the white pulp of the spleen, 
and fibrin deposition or fibrin thrombi in various organs.  
The gross lesions in young pigs experimentally 
infected with Zaire ebolavirus were pulmonary 
consolidation and enlargement of the lung-associated lymph 
nodes, which were sometimes mildly hemorrhagic. 
Microscopically, the lung lesions were identified as 
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bronchointerstitial pneumonia. The right atrium was 
hemorrhagic in some animals, although the cause of this 
lesion was uncertain. Mild lung and lymph node lesions 
were reported in some asymptomatic piglets infected with 
Reston ebolavirus, but it was not certain if they could be 
attributed to this virus. 
Diagnostic Tests 
Filovirus infections can be diagnosed by detecting 
antigens with an antigen-capture ELISA or 
immunostaining, and by detecting viral RNA with RT-PCR. 
Ebolaviruses and marburgviruses can be isolated in many 
cell lines, particularly Vero cells (viruses from pigs may not 
show cytopathic effect until the 2nd or 3rd passage). 
Electron microscopy can identify virus particles, which 
have a distinctive, filamentous pleomorphic, appearance, in 
tissues. In primates, filoviruses occur in high concentrations 
in the liver, spleen, lungs, lymph nodes and skin. Liver, 
spleen, muscle and skin have been taken from wild animal 
carcasses in good condition for surveillance. RT-PCR can 
sometimes detect ebolavirus RNA in the bones of 
decomposed carcasses. Virus isolation is more difficult: 
unpublished data suggests that carcasses decomposing in 
the African forests may contain infectious virus for only 3 
to 4 days after death. In bats, filoviruses or their nucleic 
acids have been found in tissues such as the liver and 
spleen, and sometimes in the blood.  
Serological tests that may be used to detect antibodies 
to filoviruses include ELISAs, indirect immunofluorescence 
(IFA) and immunoblotting, but neutralization tests are 
unreliable. Cross-reactions can occur, particularly between 
different species of ebolaviruses. The IFA test is thought to 
be prone to nonspecific reactions, and is uncommonly used 
at present. 
Treatment  
Because most filovirus infections are serious and often 
fatal in both humans and nonhuman primates, infected 
animals are usually euthanized.  
Control 
Disease reporting 
Animals that may be infected with ebolaviruses or 
marburgviruses must be reported immediately, to protect 
humans who may be exposed and aid in controlling the 
outbreak. 
Prevention 
Quarantine of nonhuman primates during importation 
protects humans and healthy nonhuman primates from 
exposure to filoviruses. To prevent the exportation of 
Reston ebolavirus, the government of the Philippines has 
banned wild-caught monkeys from export and established a 
quarantine period for captive-bred primates. During 
outbreaks, suspects and exposed animals should be isolated, 
and euthanized after confirmation of the disease. Strict 
infection control procedures are necessary to prevent virus 
transmission on fomites. Prevention of human exposure 
during diagnosis and eradication activities is vital, as 
humans are severely affected by most filoviruses. 
Measures to prevent infection of swine with Reston 
ebolavirus in endemic areas have not yet been established, 
but normal biosecurity measures should be helpful. Pigs 
should not be allowed to contact bats or nonhuman 
primates. 
Very little is known at present about the susceptibility 
of other species. As a precaution, some animals in the U.S. 
(e.g., pets in the home of an ebolavirus-infected human) 
may be quarantined and monitored similarly to exposed 
humans. The disposition of exposed animals may differ in 
other countries. 
Morbidity and Mortality 
In Africa, high mortality rates have been reported in 
some animal populations, including nonhuman primates 
and duikers, during some human ebolavirus epidemics. 
Outbreaks in wild animals can occur suddenly, and may 
cause widespread mortality on one area while having little 
or no impact on other regions. The effect on local 
populations can be severe. Gorilla and duiker numbers fell 
an estimated 50% in one preserve, while chimpanzee 
populations decreased by 88% during another outbreak. 
One study estimated 90-95% mortality (5000 animals) in a 
population of gorillas. Experimental inoculation of gorillas 
or chimpanzees is not done, but mortality can be very high 
in other nonhuman primates inoculated with African 
filoviruses. Nevertheless, antibodies have also been 
reported in some wild primates or wild-born captive 
primate populations, suggesting that some animals can 
recover or are resistant to disease. (However, reactivity to 
nonpathogenic filoviruses is difficult to rule out as the 
cause of these antibodies.) 
Reston ebolavirus has a case fatality rate greater than 
80% in experimentally infected cynomolgus macaques. 
Infected monkeys at quarantine facilities were euthanized 
once the outbreaks were recognized, and the cumulative 
case fatality rate is unknown; however, 82% of the animals 
with Reston virus antigens in the blood at the infected 
export facility died. The overall mortality rate was also 
higher at this facility, compared to similar uninfected 
facilities in the Philippines. The source of the infection for 
the monkeys was not found, but imported primates from the 
Philippines were virus-free after the infected export facility 
was closed in 1997. However, Reston ebolavirus was 
detected in domesticated pigs in the Philippines in 2008, 
during an investigation of a PRRS outbreak. Seroprevalence 
to Reston ebolavirus was high (approximately 70%) among 
pigs on affected farms, but no antibodies were found in pigs 
from an area unaffected by illness. The illness was reported 
to be severe in sick pigs infected with both viruses in the 
Philippines and China, but pigs inoculated experimentally 
with Reston ebolavirus alone remained asymptomatic. In 
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pigs, Zaire ebolavirus infections have currently been 
described only in experimentally infected animals less than 
2 months of age. The illness seems to be more severe in 
older piglets than one-month-old animals, which all 
survived in one experiment. 
Infections in Humans 
Incubation Period 
The precise incubation period for filovirus infections is 
difficult to determine, as the time of exposure is uncertain 
or not described in most cases. Some estimates indicate a 
potential range of 2 to 21 days, with symptoms usually 
appearing in 4 to 10 days. The initial signs occurred after 3 
to 13 days in a limited number of cases where the time of 
exposure was known. Estimates of the mean incubation 
period during outbreaks have ranged from 6 to 13 days, and 
sometimes differ even for the same outbreak. 
Clinical Signs 
Marburg marburgvirus, Zaire ebolavirus, Sudan 
ebolavirus and Bundibugyo ebolavirus appear to cause 
similar diseases, although the severity of the illness and 
most prevalent syndromes might differ with the virus. 
Published information for clinical signs during outbreaks is 
limited; however, the initial symptoms have been described 
as nonspecific and flu-like, with a high fever, chills, 
headache, severe malaise and muscle aches or generalized 
pain, followed by abdominal pain, nausea, vomiting and 
diarrhea. A nonpruritic, erythematous, maculopapular rash, 
which may develop fine scaling, can appear on the face, 
torso and extremities. Dysphagia, pharyngitis, and 
conjunctivitis or conjunctival congestion are reported to be 
common. One clinical summary described a grayish 
exudate in the pharynx, sometimes with tapioca-like 
whitish-clear granules on the soft palate. Other mucosal 
lesions, such as glossitis, gingivitis, and cold-sore like 
lesions, have been mentioned. Debilitation is often rapid, 
and generalized pain may be seen. Pregnant women may 
abort. Common changes in laboratory parameters include 
leukopenia (at the early stage) and thrombocytopenia, as 
well as elevated liver enzymes. Some patients are reported 
to experience a brief remission before deteriorating, while 
some may recover without developing more severe signs.  
After a few days, patients can develop other symptoms 
including neurological signs, dyspnea, and signs of 
increased vascular permeability, especially conjunctival 
injection and edema. Mild to severe bleeding tendencies 
may also be seen. In mild cases, this can be limited to 
bruising, bleeding of the gums, epistaxis, petechiae and/or 
mild oozing from venipuncture sites. While frank 
hemorrhaging is reported to be uncommon, it can occur, 
especially from the gastrointestinal tract. Other serious 
signs include metabolic disturbances, severe dehydration, 
diffuse coagulopathy, shock and multi-organ failure. 
Although many patients die, some begin to recover after a 
week or two. During convalescence, which can be slow, 
reported complications have included joint pain, uveitis, 
deafness, orchitis, recurrent hepatitis, transverse myelitis, 
pericarditis and mental dysfunction (e.g., psychosis). 
Secondary infections can also occur at this stage, and skin 
in the area of the rash often sloughs. One recrudescent 
infection, with encephalopathy, was reported in a patient 
who had recovered 9 months earlier. 
It should be noted that descriptions of the syndromes 
caused by filoviruses are generally limited to severe cases 
seen in hospitals, and milder cases might not have been 
observed. In rare, documented mild cases caused by 
Marburg marburgvirus, nonspecific symptoms and slight 
signs of purpura were reported in an adult, and fever, 
diarrhea, vomiting and splenomegaly in an infant. Neither 
patient was reported to be seriously ill. Evidence for 
asymptomatic seroconversion has also been documented 
rarely in ebolavirus and marburgvirus infected patients. 
Unlike other filoviruses, Reston ebolavirus does not 
seem to be pathogenic for humans. Asymptomatic 
seroconversion can be seen. 
Diagnostic Tests 
Ebola or Marburg hemorrhagic fever can be diagnosed 
by detecting antigens with an antigen-capture ELISA or 
immunostaining, and by detecting viral RNA by RT-PCR. 
Reverse transcription loop–mediated isothermal 
amplification methods have been described. Virus isolation 
can also be used (though available in limited locations) and 
electron microscopy may be helpful. In humans, filoviruses 
are most reliably detected in the blood (including serum) 
during the acute-stage of the disease, but they may also be 
found in oral fluids and in some cases in urine, breast milk, 
semen, anterior eye fluid and other body fluids, and in 
many tissues including the skin. Skin biopsies may be 
collected at post-mortem. Serological assays include ELISA 
tests, IFA and immunoblotting, but neutralization tests are 
unreliable. ELISA tests are used most often, while IFA is 
thought to be prone to nonspecific reactivity. Because the 
consequences of misdiagnosis (including false positive 
diagnosis) are severe, multiple techniques are used to 
confirm the infection whenever possible.  
Treatment 
Standard treatment currently consists of supportive 
therapy, including maintenance of blood volume and 
electrolyte balance, as well as analgesics and standard 
nursing care. 
No specific treatment has been demonstrated yet to be 
safe and effective in humans; however, experimental drugs, 
vaccines and monoclonal antibodies to filoviruses have 
been tested in animals, with varying degrees of success in 
nonhuman primates. These experimental treatments are 
diverse, and may be aimed at inhibiting virus replication 
and/or entry into cells, treating clotting abnormalities or 
sepsis, or boosting immune responses. Most experimental 
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treatments have been tested very early in the incubation 
period, but some were promising when started up to 2 days 
after exposure, or even after early clinical signs (e.g., mild 
elevation in temperature) developed. A few drugs have 
advanced to human phase I clinical trials, which are the 
initial tests to determine whether agents appear to be safe 
for human use. When supplies are available, some 
experimental treatments have been used in humans on a 
compassionate basis. 
Control 
Disease reporting 
International health regulations require that nations 
report acute hemorrhagic fever syndromes immediately to 
WHO, without waiting for the causative agent to be 
identified. Suspected human cases of Ebola or Marburg 
hemorrhagic fever should be reported immediately to the 
nation’s public health service, to prevent transmission and 
aid in case management and diagnosis. In the U.S., cases 
are reported to public health departments and to CDC's 
Special Pathogens Branch. 
Prevention 
In Africa, ebolavirus infections are often linked to 
exposure to wild animal tissues during butchering. Because 
the full host range may not be known, all sick and dead 
wild animals should be avoided (including for use as food). 
To prevent infection from animals that might be infected 
but have not yet developed obvious clinical signs, good 
personal hygiene should be used when handling and 
preparing meat, and the meat should be thoroughly cooked. 
Surveillance for deaths and illness in wild animals may 
provide an early warning to prevent human epidemics, but 
such deaths have not been seen in all human outbreaks. 
Marburg marburgvirus infections have been linked to 
exposure to caves, mines and cave-dwelling bats, but the 
means of transmission from bats to humans is still 
unknown. If contact is unavoidable (e.g., occupational 
exposure), personal protective equipment and good hygiene 
should be used. Some caves have been closed to human 
entry after human cases were recognized.  
Human epidemics have been successfully stopped in 
the past by tracing infected individuals, and isolating 
patients in facilities with barrier nursing procedures and 
strict infection control measures. Healthcare workers should 
use the personal protective equipment currently 
recommended by experts (e.g., gloves, gowns, masks, eye 
protection and other equipment) to prevent exposure to 
blood and body fluids. Burial practices should avoid all 
contact with the body or fomites. During convalescence, the 
possibility of exposure during breastfeeding or sexual 
intercourse should be considered. Ebolaviruses have been 
found in milk 15 days after the onset of illness (although 
the maximum period of shedding is unknown), and in the 
semen of 26% of men after 7-9 months. Sexual abstinence 
has been recommended for 12 months after recovery, or 
until two tests find no viral RNA in semen. Currently, the 
WHO does not recommend breast-feeding during the acute 
stage of the illness, and suggests that women also refrain 
from breast-feeding if they have evidence for virus in the 
milk after recovery, until viral RNA is no longer 
demonstrated.  
Reston ebolavirus is not known to affect humans. As a 
precaution, tissues from infected animals should not be 
eaten or handled. Good hygiene and appropriate personal 
protective equipment should be used if these animals or 
their tissues must be handled. 
Morbidity and Mortality 
Illnesses caused by filoviruses have occurred as 
isolated cases, small clusters of cases, or large outbreaks 
which may affect hundreds of people. The 2013-2016 
outbreak is unusual in its scale, having affected thousands. 
Some outbreaks seem to originate with a single person, 
while multiple transmission events have been reported in 
others. High risk activities include butchering wild animals 
and visiting caves and mines. Outbreaks can be propagated 
by transmission to family members and other close contacts 
through nosocomial transmission, unsafe self-treatment at 
home, funeral practices and other routes. Healthcare 
workers are at high risk, as hospital supplies are limited in 
some areas where filoviral diseases occur, and barrier 
nursing practices may be inadequate. Other factors that help 
propagate the disease include poor availability of 
healthcare, reluctance to see a medical practitioner, and 
difficulty in distinguishing some cases from other serious 
illnesses, particularly in the early stages. As a result, some 
outbreaks have been identified months after they began. 
Delayed identification, together with the introduction of the 
virus into urban areas, and socioeconomic factors (e.g., 
poverty and healthcare-associated risk factors), are thought 
to have fueled the current outbreak in West Africa. 
Outbreaks of Ebola hemorrhagic fever are reported 
periodically in Africa. The number of reported outbreaks 
has increased, due either to a higher incidence or better 
recognition of the disease. Marburg hemorrhagic fever was 
only recently recognized as a serious and recurring problem 
in humans. This disease was initially recognized in 1967, 
during an outbreak in laboratory workers exposed to 
infected primate tissues. Only 6 cases were described 
during the following 3 decades, 3 cases in travelers to 
Africa and three in their contacts. In 1998, however, this 
virus caused an epidemic affecting hundreds of people in 
the Democratic Republic of the Congo (DRC). This 
outbreak was associated with a mine where infected bats 
were later discovered. Several different viral strains were 
isolated during the epidemic, suggesting that the virus had 
been introduced repeatedly into the population via infected 
miners. This outbreak also uncovered a pattern of 
hemorrhagic disease in the mine dating to 1987 or earlier, 
and one survivor of an earlier outbreak was found to have 
antibodies to this virus. In 2004-2005, another large 
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outbreak was reported in Angola, where Marburg 
marburgvirus was not thought to exist. Unlike the previous 
outbreak, it seems to have originated with a single person, 
and was propagated by person-to-person transmission. 
Several additional cases have been reported since that time, 
in miners or travelers who visited caves. 
Case fatality rates are usually high for African 
filoviruses, and the prognosis is poor in patients who 
become severely ill. Zaire ebolavirus is thought to be the 
most pathogenic virus, with case fatality rates from 
outbreaks in Africa ranging from 44% to 88%. Sudan 
ebolavirus appears to somewhat be less virulent, with a case 
fatality rate estimated to be 41-65%, (or 26-54%, depending 
on the cases included). However, higher mortality rates 
have been reported in small numbers of Sudan ebolavirus-
infected individuals who were not treated. The reported 
case fatality rate was 36% in the initial outbreak caused by 
Bundibugyo ebolavirus. It varies widely in Marburg 
hemorrhagic fever, from 22-23% during the 1967 
laboratory-associated outbreak in Europe, to 83% (56% in 
laboratory-confirmed cases) during the outbreak in DRC, 
and 88% in Angola. It is not known whether higher 
mortality rates are associated with more virulent filoviruses 
(or strains of these viruses), higher doses of virus, 
concurrent malnutrition and disease, or the availability and 
quality of healthcare. Only a limited number of cases have 
been treated in Western countries with advanced healthcare 
facilities.  
The incidence of mild or asymptomatic infections is 
still uncertain. Asymptomatic infections have been 
documented in rare cases, and the possibility of such 
infections is also suggested by reports of antibodies and 
cell-mediated immune responses to filoviruses in people 
who have no history of Ebola or Marburg hemorrhagic 
disease. Seroprevalence rates tend to be higher in groups 
that have more contact with wild animals or live in rural 
forest ecosystems. However, illnesses without hemorrhages 
might have been misdiagnosed as other diseases such as 
malaria, which can also be severe. Cross-reactivity with 
other viruses may also be a problem in serological tests. In 
particular, there may be undiscovered filoviruses in Africa 
(and other locations) that are less pathogenic or 
nonpathogenic for humans. 
Seroconversion to Reston virus does not seem to be 
common. In the Philippines, seroprevalence rates ranged 
between 1% and 4% (overall 2%) in people who had been 
exposed to either nonhuman primates or infected pigs. All 
of the primate-exposed positive samples came from people 
associated with the single export facility known to have 
housed infected animals. 
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